Amgen Inc (NASDAQ:AMGN) Q4 2022 Earnings Call dated Jan. 31, 2023. Corporate Participants: Arvind Sood -- Vice President, Investor Relations Robert A. Bradway -- Chairman
Amgen Inc.
-(AMGN)
XNAS:AMGN
AMGN Infographic: Amgen’s Q4 2022 profit drops on flat revenues
Amgen Inc. (NASDAQ: AMGN) said its revenues remained unchanged in the fourth quarter of 2022 when the biotechnology firm's earnings declined. Unadjusted
Amgen Inc (AMGN) Q3 2022 Earnings Call Transcript
Amgen Inc (NASDAQ:AMGN) Q3 2022 Earnings Call dated Nov. 03, 2022. Corporate Participants: Arvind Sood -- Vice President of Investor Relations Bob Bradway -- Chairman &
Amgen Inc. (AMGN) Q2 2022 Earnings Call Transcript
Amgen Inc. (NASDAQ: AMGN) Q2 2022 earnings call dated Aug. 04, 2022 Corporate Participants: Arvind Sood -- Vice President, Investor Relations Robert A. Bradway -- Chairman
Earnings calendar for the week of August 2
Labor market conditions improved once again and jobless claims dropped to about 400,000 after rising last week, as economic activity picked up.
Amgen Inc. (AMGN) Q1 2021 Earnings Call Transcript
Amgen Inc. (NASDAQ: AMGN) Q1 2021 earnings call dated Apr. 27, 2021 Corporate Participants: Arvind Sood -- Vice President, Investor Relations Robert A. Bradway -- Chairman
Here’s what you need to know before investing in Amgen (AMGN)
The coronavirus outbreak has made leading pharma companies channelize their resources for vaccine development, and the efforts have been largely successful. While
Amgen Inc (AMGN) Q4 2020 Earnings Call Transcript
Amgen Inc (NASDAQ: AMGN) Q4 2020 earnings call dated Feb. 02, 2021. Corporate Participants: Arvind Sood -- Vice President, Investor Relations Robert A. Bradway -- Chairman
Earnings calendar for the week of February 1
In a week that saw one of the worst stock selloffs, Gamestop came under spotlight after the stock experienced unprecedented fluctuations, marked
Earnings calendar for the week of January 11
Stock markets responded positively to the latest developments in presidential election. On the heels of the Dow Jones Industrial Average achieving a
Amgen Inc. (AMGN) Q3 2020 Earnings Call Transcript
Amgen Inc. (NASDAQ: AMGN) Q3 2020 earnings call dated Oct. 28, 2020 Corporate Participants: Arvind Sood -- Vice President of Investor Relations Robert A. Bradway -- Chairman
Amgen Inc. (AMGN) Q2 2020 Earnings Call Transcript
Amgen Inc (NASDAQ: AMGN) Q2 2020 earnings call dated July 28, 2020 Corporate Participants: Arvind Sood -- Vice President of Investor Relations Robert A.
Amgen Inc (NASDAQ: AMGN) Q1 2020 Earnings Call Transcript
Amgen Inc (AMGN) Q1 2020 earnings call dated Apr. 30, 2020 Corporate Participants: Arvind Sood -- Vice President of Investor Relations Robert A. Bradway -- Chairman
A visual dashboard of Amgen’s (AMGN) Q1 2020 earnings results
Amgen's (NASDAQ: AMGN) top and bottom line in the first quarter of 2020 beat analysts' estimates. The biotech firm's adjusted earnings per
Amgen Inc (NASDAQ: AMGN) Q4 2019 Earnings Call Transcript
Amgen Inc (NASDAQ: AMGN) Q4 2019 Earnings Conference Call January 30, 2020 Corporate Participants: Arvind Sood -- Vice President of Investor Relations Robert A. Bradway -- Chairman
Amgen beats in Q3, raises guidance
Amgen Inc (NASDAQ: AMGN) reported third-quarter 2019 adjusted EPS of $3.66 on revenue of $5.74 billion. This was better than analysts’ prediction
Amgen to take over Celgene’s OTEZLA for $13.4 billion; Bristol-Myers Squibb increases share buyback plan
Bristol-Myers-Squibb (NASDAQ: BMY) announced that Amgen (NASDAQ: AMGN) will acquire Celgene's (NASDAQ: CELG) Otezla business for $13.4 billion in a cash transaction.
Amgen beats Q2 earnings and revenue estimates
Amgen Inc. (NASDAQ: AMGN) reported second quarter 2019 adjusted EPS of $3.97 on revenue of $5.9 billion. Analysts had predicted the biotechnology
Top biotech stocks to be considered for investment this year
When the massive selloff battered Wall Street in the final months of 2018, biotechnology stocks were no exception. And, most of them
What’s in store for top pharma stocks this year
The stocks of leading pharmaceutical firms shifted to growth mode this year after winding up 2018 on a low note, in line
Amgen Q1 earnings beat Street view; lifts full-year earnings guidance
Biotechnology firm Amgen (Nasdaq: AMGN) reported first-quarter earnings that increased from last year and exceeded estimates, while revenues remained unchanged. Meanwhile, the management